secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001171843-22-007974
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose reports tuspetinib CRs across 4 dose levels in r/r AML; establishes $50M ATM facility
--------------------------------------------------------------------------------

- Tuspetinib monotherapy yielded 38.1% response in FLT3+ and 19% in FLT3-WT r/r AML across 40-160mg doses.
- Luxeptinib G3 formulation shows up to 18-fold bioavailability improvement; continuous dosing initiated in AML patients.
- Aptose entered ATM equity distribution agreement with JonesTrading for up to $50M common share sales on Nasdaq.
- Tuspetinib selected 120mg as monotherapy expansion dose and 80mg for venetoclax combo in APTIVATE trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184322007974/0001171843-22-007974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184322007974/f8k_120922.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer